Posted on July 21, 2008 by crimsoncanary
Data publsihed in the Annals of Oncology show that Tarceva (erlotinib) salvage therapy can be an option in some NSCLC patient subsets after Iressa (geftinib) failure.
Filed under: Uncategorized | Tagged: AstraZeneca, EGF kinase, ErbB-1, ErbB1, erlotinib, gefitinib, Genentech, Iressa, kinase, OSI, Roche, Tarceva | Comments Off
Posted on July 21, 2008 by crimsoncanary
Exelixis have initiated a phase III trial of MET/RET/VEGFR2 inhibitor XL184 for the treatment of medullary thyroid cancer.
Filed under: kinase | Tagged: Exelixis, kinase, Met, phase iii, RET, VEGFR2, XL-184, XL184 | Comments Off
Posted on July 21, 2008 by crimsoncanary
Roche have made an offer to buyout remaining shares of Genentech for $89.00 per share, or a total value of $43.7 billion
Filed under: kinase | Tagged: Acquisition, Avastin, Genentech, kinase, Merger, Roche | Comments Off
